Department of Clinical Epidemiology, University Hospital Maastricht, Maastricht, The Netherlands.
Dermatol Surg. 2010 Dec;36(12):1950-5. doi: 10.1111/j.1524-4725.2010.01805.x. Epub 2010 Nov 11.
Basal cell carcinoma (BCC) is a slowly growing nonmelanoma type of skin cancer that often is located on the face. Different therapies are available to treat BCC, of which surgical excision (SE) and Mohs micrographic surgery (MMS) are the most frequently used surgical procedures.
To examine which attributes of a surgical treatment the general public values as important and to determine the incremental willingness to pay for MMS versus SE.
A discrete-choice experiment (DCE) was conducted among members of the general public to examine which attributes of a surgical treatment for primary BCC are valued as important. In addition, based on the attributes included in the experiment, the willingness to pay for MMS versus SE was determined.
Respondents (N=312) preferred a treatment with a lower recurrence rate, shorter surgery time, shorter travelling time, shorter waiting time, no risk for re-excision, and lower cost. The incremental willingness to pay for MMS was 847 euro ($1,203).
Results from this DCE indicate that, when outcome and process attributes are considered from a societal perspective, MMS is preferred over SE for primary BCC. The authors have indicated no significant interest with commercial supporters.
基底细胞癌(BCC)是一种生长缓慢的非黑色素瘤皮肤癌,通常位于面部。有多种治疗方法可用于治疗 BCC,其中手术切除(SE)和 Mohs 显微外科手术(MMS)是最常用的手术方法。
调查公众认为哪种手术治疗的属性重要,并确定 MMS 相对于 SE 的额外支付意愿。
在普通公众中进行了一项离散选择实验(DCE),以调查原发性 BCC 手术治疗的哪些属性被认为是重要的。此外,基于实验中包含的属性,确定了 MMS 相对于 SE 的支付意愿。
受访者(N=312)更喜欢复发率较低、手术时间较短、旅行时间较短、等待时间较短、无再次切除风险和成本较低的治疗方法。MMS 的额外支付意愿为 847 欧元(1203 美元)。
这项 DCE 的结果表明,从社会角度考虑结果和过程属性时,MMS 优于 SE 用于原发性 BCC。作者表示没有与商业支持者的重大利益关系。